Search research articles
Contact Us
Filters
Showing results (21-30 of 36) with videos related to
Page
of 4
Sort By:
Journal of Medicinal Chemistry
|
October 17, 2003
Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors
Rachel R Kroe, John Regan, Al Proto, et al.
Biochemical Pharmacology
|
December 13, 1996
Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase
D D Jeanfavre, J R Woska, C A Pargellis, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 23, 2008
Synthesis and SAR studies of indole-based MK2 inhibitors
Zhaoming Xiong, Donghong Amy Gao, Derek A Cogan, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 9, 2008
Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase
D A Cogan, R Aungst, E C Breinlinger, et al.
Nature Structural Biology
|
March 16, 2002
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Christopher Pargellis, Liang Tong, Laurie Churchill, et al.
Biochemistry
|
August 4, 2004
Catalysis and function of the p38 alpha.MK2a signaling complex
Susan M Lukas, Rachel R Kroe, Jessi Wildeson, et al.
Biochemistry
|
September 15, 2004
Discovery and characterization of a substrate selective p38alpha inhibitor
Walter Davidson, Lee Frego, Gregory W Peet, et al.
Biochemical Pharmacology
|
November 26, 2008
Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling
Lore M Gruenbaum, Racheline Schwartz, Joseph R Woska, et al.
Journal of Medicinal Chemistry
|
June 28, 2002
Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate
John Regan, Steffen Breitfelder, Pier Cirillo, et al.
British Journal of Haematology
|
December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth
Hiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 36) with videos related to
Sort By:
Page
of 4
Journal of Medicinal Chemistry
|
October 17, 2003
Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors
Rachel R Kroe, John Regan, Al Proto, et al.
Biochemical Pharmacology
|
December 13, 1996
Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase
D D Jeanfavre, J R Woska, C A Pargellis, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 23, 2008
Synthesis and SAR studies of indole-based MK2 inhibitors
Zhaoming Xiong, Donghong Amy Gao, Derek A Cogan, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 9, 2008
Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase
D A Cogan, R Aungst, E C Breinlinger, et al.
Nature Structural Biology
|
March 16, 2002
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Christopher Pargellis, Liang Tong, Laurie Churchill, et al.
Biochemistry
|
August 4, 2004
Catalysis and function of the p38 alpha.MK2a signaling complex
Susan M Lukas, Rachel R Kroe, Jessi Wildeson, et al.
Biochemistry
|
September 15, 2004
Discovery and characterization of a substrate selective p38alpha inhibitor
Walter Davidson, Lee Frego, Gregory W Peet, et al.
Biochemical Pharmacology
|
November 26, 2008
Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling
Lore M Gruenbaum, Racheline Schwartz, Joseph R Woska, et al.
Journal of Medicinal Chemistry
|
June 28, 2002
Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate
John Regan, Steffen Breitfelder, Pier Cirillo, et al.
British Journal of Haematology
|
December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth
Hiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.
Page
of 4